Delivery Order SPE2DB25D3201-SPE2DB26FNNPX
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 2, 2025, for the supply of Dalvance 500 mg vials with a contract ceiling value of $3,647.09. This is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and was funded through the Defense Logistics Agency's Medical Supply Chain. The award was made through competitive procurement with no set-aside designation....
- The Defense Logistics Agency awarded a $5,961.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dalvance 500 mg vials, with an ultimate completion date of September 10, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,008.78 firm fixed-price delivery order is for the supply of DALVANCE 500 MG VIALS, a pharmaceutical product, with a completion date of May 20, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- The Defense Logistics Agency awarded a $4,481.35 delivery order to AmerisourceBergen Drug Corp for 500 mg Dalvance vials on April 22, 2025, with a completion date of April 23, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dalvance 500 mg vials, with a ceiling value of $2,743.74. The award, issued on September 4, 2025, was competitively awarded with no set-aside designation and is structured as a firm fixed price delivery order with an ultimate completion date of September 5, 2025. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $12,552.47 firm fixed price delivery order to AmerisourceBergen Drug Corp for DALVANCE 500 mg vials, with an ultimate completion date of October 24, 2025. The award was made without set-aside designation through competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor supporting federal medical procurement needs, particularly for military and veteran healthcare systems....
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The award, valued at $6,930.64, is for the supply of DALVANCE 500 MG VIALS, a pharmaceutical product. The contract has a completion date of August 7, 2024 and uses a Firm Fixed Price pricing type. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government,...
- This is a $7,170.24 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DALVANCE 500 MG VIALS, a pharmaceutical product, with a completion date of May 28, 2025. The contract is not set aside and is an open competition award. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award, valued at $36,921.23, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order, with a Firm Fixed Price pricing type, for the provision of DALVANCE 500 MG VIALS. The contract has an ultimate completion date of March 5, 2025 and was awarded on March 4, 2025. There was no set-aside designation used for this contract. AmerisourceBergen holds a...
- This federal contract award, with an award ID of SPE2DX15D3404 and SPE2DX24F0YDZ, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The $5,204.53 firm fixed-price delivery order is for the pharmaceutical product DALVANCE 500 MG VIALS, with a completion date of November 3, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that is a key vendor for federal healthcare...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB26FNNPXDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 24, 2025, for the supply of Dalvance 500 mg vials, a specialty antibiotic medication. This firm fixed-price delivery order, valued at $5,719.88 with an ultimate completion date of October 27, 2025, was competitively awarded without set-aside designation. The award represents a child contract under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion prime vendor agreement running through December 2026 that authorizes the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs. The broader contract vehicle enables AmerisourceBergen to serve the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems with an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 10/24/25 |